MAPK7 and glioma: To further validate ERK5 as promoting TMZ resistance in glioma cells and to discount potential off-target RNAi effects, we used siPOOLs consisting of 30 individual low nM siRNA that have been shown to give effective knockdown at low total nM concentrations (Figure S1B) with reduced off-target effects [22].